Building High-Impact Vendor Partnerships to Accelerate Cell Therapy Execution

  • Building phase-appropriate quality systems with defined quality indicators to enable earlystage cell therapy development
  • Embedding quality indicators into vendor selection and supplier partnerships to protect execution
  • Leveraging quality indicators as strategic tools for risk management and operational agility